Sonoma Pharmaceuticals

NASDAQ SNOA
$4.73 0.20 4.42%
Today share price
USA
Sector: Healthcare Industry: Pharmaceuticals
Get access
to the rating of Finrange stocks
With this tariff you will be able to use the service without restrictions, all information will be available
Get 7 days free

Rating Finrange

Index: 35 %
Market cap Market capitalization – refers to the total value of all a company's shares of stock. It is calculated by multiplying the price of a stock by its total number of outstanding shares.
2.72M
EV Enterprise value is a measure of a company's total value, often used as a more comprehensive alternative to equity market capitalization. Enterprise value includes in its calculation the market capitalization of a company but also short-term and long-term debt as well as any cash on the company's balance sheet.
-2.38M
Beta Beta is one of the most popular indicators of risk is a statistical measure. Analysts use this measure often when they need to determine a stock's risk profile.
1.38
Shares Shares outstanding refer to a company's stock currently held by all its shareholders, including share blocks held by institutional investors and restricted shares owned by the company’s insiders.
1.24M
YTD Year to date (YTD) refers to the period of time beginning the first day of the current calendar year or fiscal year up to the current date. he acronym often modifies concepts such as investment returns and price change.
75.84 %

Upcoming events Sonoma Pharmaceuticals

All events
No upcoming events scheduled

Stock chart Sonoma Pharmaceuticals

Stock analysis Sonoma Pharmaceuticals

Indicator Company Industry
P/E (LTM) Shows how many years the investor's investment in the company will pay off with a profit over the last 12 months.
-0.79 -1.50
P/BV (LTM) Shows the ratio of the market price of the share to the current book value.
0.40 1.38
EV/EBITDA (LTM) Represents the ratio of the company's value to its pre-tax EBITDA in the last 12 months.
0.86 -0.54
Net Debt/EBITDA (LTM) A company's debt ratio, which indicates how long the company will need to run on cash flow in the past 12 months to pay off its own debt.
1.84 0.35
ROE (LTM) Shows the efficiency of using the share capital by the company. In other words, ROE shows how much of the company's net profit for the invested capital over the last 12 months.
-78.37 -27.86

Price change Sonoma Pharmaceuticals per year

1.88$ 5.35$
Min Max

Summary analysis Sonoma Pharmaceuticals

Get access
to the rating of Finrange stocks
With this tariff you will be able to use the service without restrictions, all information will be available
Get 7 days free

Shareholder structure Sonoma Pharmaceuticals

Revenue and net income Sonoma Pharmaceuticals

All parameters

About company Sonoma Pharmaceuticals

Sonoma Pharmaceuticals, Inc., develops and produces stabilized hypochlorous acid (HOCl) products for various applications, including wound care, animal health care, eye care, oral care, and dermatological conditions in the United States and internationally. The company offers Epicyn, an antimicrobial facial cleanser; Levicyn, an HOCl based prescription product to manage and relieve burning, itching, and pain experienced with various types of dermatoses; Celacyn gel, a product indicated to promote healing through the management of new and old scars; and SebuDerm to manage and relieve the burning, itching, pain, and distraction associated with seborrhea and seborrheic dermatitis. It also provides Acuicyn, a HOCl-based product indicated to relieve itch and inflammation while helping to keep areas around the eye clean; and Microcyn, a line of products to stimulate expedited healing by targeting various pathogens, as well as antibiotic-resistant strains that slow natural healing of wounds. In addition, the company offers MicrocynAH, an HOCl-based solution designed to relieve common symptoms of hot spots, scratches, skin rashes post-surgical sites, and irritated animal skin for healing; Microdacyn60 oral care solution for the treatment of mouth and throat infections; Lasercyn gel intended for the management of minor skin irritations; MucoClyns for the use in emergencies and safe to use on mucous membranes, cuts, abrasions, burns, and body surfaces; Endocyn root canal irrigation solutions; Pediacyn atopic dermatitis hydrogel; Gramaderm for the treatment of topical mild to moderate acne; Microsafe, a surface disinfectant; and Sinudox for nasal irrigation, including moistening of cuts, abrasions, and lacerations located in the nasal cavity. The company was formerly known as Oculus Innovative Sciences, Inc. and changed its name to Sonoma Pharmaceuticals, Inc. in December 2016. Sonoma Pharmaceuticals, Inc. was incorporated in 1999 and is based in Woodstock, Georgia.
Address:
645 Molly Lane, Woodstock, GA, United States, 30189
Company name: Sonoma Pharmaceuticals
Issuer ticker: SNOA
ISIN: US83558L2043
Country: USA
Exchange: NASDAQ
Currency: $
IPO date: 2007-01-25
Sector: Healthcare
Industry: Pharmaceuticals
Site: https://www.sonomapharma.com